A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 112 participants.

Also called NCT04349072

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 112 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04349072
Other papers using this trial's data
  • Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks Circulation, 2023-03-14 DOI, PubMed 36335531
  • Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM Circulation, 2025-05-13 DOI, PubMed 39556124, PMC12063683 PubMed links an erratum for this paper. Erratum: PMID 40354453 In the PMC Open Access subset under CC BY.
  • Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial JAMA cardiology, 2023-10-01 DOI, PubMed 37639243, PMC10463171 Not in the PMC Open Access subset.
  • Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM: Insights From the VALOR-HCM Trial JACC. Cardiovascular imaging, 2025-03 DOI, PubMed 39254622
  • Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study Circulation. Cardiovascular imaging, 2022-12 DOI, PubMed 36335645
  • Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy Journal of the American College of Cardiology, 2022-07-12 DOI, PubMed 35798455
  • Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial Circulation. Cardiovascular imaging, 2024-09 DOI, PubMed 39221824, PMC11410149 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04349072. Randomized; quadruple masking; primary purpose treatment. Start 2020-07-06 (actual); primary completion 2022-02-07 (actual). Results posted on 2023-03-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
Acronym
VALOR-HCM
Condition
HOCM, Hypertrophic Obstructive Cardiomyopathy
Intervention (Drug)
Mavacamten
Intervention (Drug)
Placebo
Lead sponsor
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct04349072
Content hash
ec5c1671c0410cf458845ead46d3ba389406a73ca61eba1612004d31a6d2e318